Objectives: This study sought to examine nevirapine hypersensitivity (NVP HSR) phenotypes and their relationship with differing MHC Class I and Class II alleles and the associated CD4+ and CD8+ T cell NVP specific responses and their durability over time. Methods: A retrospective cohort study compared HIV+ patients with NVP HSR, defined by fever and hepatitis and/or rash, with those tolerant of NVP > 3 months. 
INTRODUCTION
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination HIV therapy with an excellent long-term safety profile. A treatment-limiting hypersensitivity syndrome (NVP HSR) characterized by fever, and/or rash and/or hepatitis and often accompanied by eosinophilia occurs in 5% of those starting NVP [1, 2] . NVP HSR is suggested to be T-cell mediated by both human and rat models. In rats, the sensitivity to NVP-induced skin rash can be transferred with CD4+ T cells from NVP-rechallenged rats to naive recipients and partial depletion of CD4+ T cells delays and decreases the severity of the rash. This is consistent with the decreased incidence of rash in patients with a low CD4+ T cell count [3] [4] [5] [6] [7] [8] [9] .
A CD4+ dependent-MHC Class II restricted immune response directed against NVP was first reported in Caucasians as the association of hepatic symptoms with a combination of CD4+ T cells > 25% and HLA-DRB1*01:01 [10] . Multiple class I and/or II MHC associations have now been described with different phenotypes of NVP HSR across several ethnicities [11] [12] [13] [14] [15] [16] [17] [18] [19] . These differing Class I and Class II HLA associations with different NVP HSR phenotypes across distinct populations and the increased risk of cutaneous phenotypes of NVP HSR in African Americans with CYP2B6 561 G>T [20] suggest that genetic, immunological and metabolic pathways may be important. NVP may trigger class I-restricted CD8+ or class-II restricted CD4+
T-cell mediated immune responses in the presence of the relevant class I and II major histocompatibility complex alleles, respectively.
METHODS
As part of a prospective cohort study we identified the association of class I and II HLA alleles with clinical and immunological phenotypes of NVP HSR.
Patient and Control population
Definitive ascertainment of NVP-associated reaction status was achievable in 375 of 451 individuals in the West Australian HIV Cohort identified as NVP-exposed.
Ethnicity and/or HLA genotyping was unavailable for 54 of these individuals and 41 individuals lacked clinical information required as part of the inclusion criteria. Associations between HLA alleles, severity of CD4+ T lymphocyte-dependent immune deficiency and predisposition to NVP HSR were explored in analyses restricted to Asians and Caucasians without symptoms after 3 months NVP exposure (n = 262) or who had developed NVP-induced drug reactions (n=19) ( Table 1) . NVP-associated reactions were identified prospectively in the database, and the case definition was retrospectively validated by a clinician blinded to HLA typing, who utilized standardized diagnostic criteria, including a minimum of fever in combination with rash and/or hepatitis (grade 2 toxicity or greater: alanine aminotransferase >2.5 times the upper limit of normal) and/or eosinophilia (eosinophils > 0. 5 
HLA Typing
HLA A B C and DR, DQ typing was performed using sequence base typing as previously described [21] .
Isolation of Nevirapine and 12-OH-NVP
NVP solution was prepared by dissolving 200 mg NVP tablets (Viramune, BoehringerIngelheim) in DMSO and the absorbance at 260nm was checked with the nanodrop spectrophotometer. The NVP stock solution was diluted to 1mg/ml in PBS, filtered and resuspended 1:10 in culture medium (10%FCS-RPMI-1604) and added to cell cultures in the ELISpot assay at a final concentration of 40m. The 12-OH-NVP metabolite was prepared similarly and then added to cell cultures at 50m final concentration.
T-Cell depletions and IFNELISpot assay
PBMC were depleted of T cells using CD4 or CD8 or CD25 Dynal beads (Invitrogen) according to the manufacturer's instructions. Cryopreserved PBMC were thawed and left to settle overnight or freshly isolated PBMC were used in the T-cell depletion assays. The T-cell depleted fractions were counted prior to use in the ELISpot assay.
Specific CD4, CD8 or CD25 high T-cell depletions were confirmed by flow cytometry (Gallios Flow Cytometer, Beckman Coulter).
The IFN ELISpot assay was performed in triplicate as described previously using NVP and 12-OH NVP at final concentrations of 40m and 50m respectively [22] . A positive response was defined as greater than 50 spots/million cells after background removal [23] .
Intracellular cytokine staining
Intracellular cytokine staining (ICS) was set up at 2 million cells/ml with either 40m NVP or 50m 12-OH-NVP, and positive (PHA) and negative controls (cells alone).
Brefeldin A (20g/ml) was added after 2 hours. The reaction was stopped after 6 hours.
Cells were then washed and 10ls each of CD4 and CD8 fluorochrome-conjugated antibodies (CD4-PE and CD8-APC-H7) were added (20minutes room temperature).
Cells were fixed and permeablised using Intraprep reagents 1 and 2 (Beckman coulter), 
RESULTS
19 patients (13 Caucasian, 6 Asian) were identified with NVP HSR (Figure 1 ).
Reactions to NVP were more prevalent amongst the fully ascertained Asians (P = 0.009, Fisher exact test), but comparisons of the NVP sensitive and tolerant patient groups did not show any significant within-race differences in terms of age, sex, or clinical and immunological factors (Table 1) .
Genetic analysis
The association of the alleles HLA-Cw*04, -Cw*08 and -B*3501 with NVP HSRs move in the same direction in both Asians and Caucasians ( Table 2 , Table S2 
CD4+ and CD8+ T cells play dual roles in NVP HSR
T-cell depletion studies showed that both CD4+ and CD8+ T cells contributed to the NVP-specific immune response ( Figure 3A) . It is still unclear whether the HLA-B*35 and HLA-Cw*04 associations with NVP HSR featuring rash are independent allele or haplotype effects and whether associations between HLA alleles and NVP HSR may be confounded due to linkage disequilibrium with other genes on chromosome 6. In our cohort, the numbers are too small to perform linkage analysis between the two markers, however the 6/7 individuals who carried the HLA-Cw*04 allele also carried HLA-B*35:01. Some studies have identified HLA-Cw*04 as significant but not examined HLA-B*35 [15, 19] , while others have implicated both alleles in Asian populations [20] . Individual allele analysis and a GWAS in relation to NVP induced rash in a Thai cohort showed that HLA-B*35:05 and HLA-Cw*04 were higher in the HSR group, however only HLA-B*35:05 remained significant with correction [18, 19] . Another group more recently reported an association between NVP SJS/TEN and HLA-C*04:01 in a Malawian population however SJS/TEN is a rare reaction with a differing immunopathogenesis that was not seen in our NVP HSR study [14] .
Alleles outside of the MHC may contribute to phenotype specific adverse reactions observed for NVP. A GWAS and independent replication studies revealed 5 SNPs on chromosome 6 that were significantly associated with NVP-induced rash within a 30kb region containing the CCHCR1 gene, and 2 SNPs within the gene significantly associated with rash [27] . Complete screening of the CCHCR1 locus found one nonsynonymous SNP, rs1576, significantly associated with NVP induced rash. The CCHCR1 locus has previously been associated with psoriasis susceptibility and may be involved in keratinocyte proliferation [28] . Thus, it is likely that this association is specific to the rash phenotype of NVP HSR. Although the CCHCR1 gene is located 110 kb telomeric from the HLA-C locus and 210 kb from the HLA-B locus, logistic regression analysis indicated that the association of SNPs in the CCHCR1 gene with nevirapine-induced rash was independent from that of the HLA-B*3505 allele [27] .
This study raises the issue that other genetic associations may also contribute to phenotpye specific NVP HSR.
Polymorphism in drug metaboising enzymes and in particular CYP2B6 516GT and 983TC have been shown to be associated with NVP exposure [29] [30] [31] . Some who have not considered HLA have not shown a direct relationship between oral clearance and development of NVP HSR [29] while others have shown, cutaneous adverse events have been associated with CYP2B6 516GT HSR in African Americans carrying HLA-Cw4 [32] . This suggests that the development of class I mediated NVP HSR is dependent on HLA carriage as well as accumulation of the parent drug. In contrast, hepatic symptoms have not been linked to such metabolism and suggest a MHC Class II restricted CD4+ T-cell dependent mechanism [20] . Although, nevirapine has also shown to be a substrate for efflux transporter ABCC10, and genetic variants influence plasma concentrations, the clinical implication is not yet known [33] . Prolonged exposure to any antiretroviral therapy, coinfection with hepatitis C virus (HCV) and abnormal baseline levels of alanine aminotransferase place patients at a higher risk of developing hepatotoxicity due to NVP explosure [34, 35] , however HCV and HBV coinfection were excluded in our cohort for individuals with hepatotoxicity.
Animal studies also highlight the duality of the immune response to NVP in hypersensitivity. In the NVP rash model, rats show no evidence of hepatotoxicity and animal T cells produce INF in response to NVP rather than to 12-OH-NVP [36] . Taken together with the responses seen here in systemic NVP-HSR patient PBMCs, the evidence suggests another pathway for induction of the systemic immune response.
Keratinocytes can upregulate the expression of MHC Class I/II molecules on APCs and stimulate antigen-experienced T cells, however the consensus is that they are unlikely to be able to prime new T-cell responses [37] . Thus, it would appear that the mechanism in the NVP induced skin rash may propagate systemic stimulatory signals for T cells activated by NVP via another pathway.
The rapid waning of ex vivo responses to NVP supports a delayed type hypersensitivity model in which drug induced T-cell activation is mediated by the associated HLA allotypes. Naive T cells are primed on initial exposure to NVP and a memory pool is restimulated on repeat exposure. We suggest that a required threshold of NVP specific memory cells are necessary in order to stimulate a response ex vivo, or perhaps that a second antigen specific T-cell activating signal/pro-inflammatory stimulus is required to 
